Evoke Pharma (NASDAQ:EVOK) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Evoke Pharma, Inc. (NASDAQ:EVOK)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.49 and traded as low as $4.28. Evoke Pharma shares last traded at $4.70, with a volume of 153,973 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Wednesday. They set a “sell” rating on the stock.

Evoke Pharma Stock Up 7.6 %

The stock has a market cap of $7.00 million, a P/E ratio of -0.43 and a beta of 0.36. The business has a 50 day moving average price of $5.12 and a 200 day moving average price of $5.49.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.